BMS to divest Celgene drugs to speed delayed deal
Bristol-Myers Squibb said it is planning to sell Otezla, Celgene's treatment for certain types of psoriasis and psoriatic arthritis, in an effort to address Federal Trade Commission concerns about its pending merger with Celgene.
Authors: Krajewska-Włodarczyk M, Owczarczyk-Saczonek A, Placek W Abstract Introduction: Fatigue is an important and underrated symptom of many chronic diseases. Aim: The evaluation of incidence and severity of fatigue as well as the influence of selected factors on fatigue in patients with psoriasis and psoriatic arthritis (PsA). Material and methods: The study included 60 patients with PsA, 58 patients with psoriasis and 61 persons in the control group aged 35-70 years. Assessment of fatigue was conducted using a fatigue subscale from the FACIT-F questionnaire. Severity of skin lesions and arthritis was d...
Conclusions: Interleukin-6 may be an indicator of inflammatory activity in psoriasis. Moreover, IL-6 may be related to lipid abnormalities in patients with this disease. PMID: 32467682 [PubMed]
PSORIATIC arthritis is a long-term condition that may result in deformed joints. The auto-immune condition can stem from the skin condition psoriasis. Here's everything you need to know.
Genome-wide association studies have demonstrated associations between susceptibility to psoriasis and single nucleotide polymorphisms (SNPs). Part of the genetic susceptibility can be explained by the established susceptibility locus in the human leukocyte antigen complex on chromosome 6p21.3, as well as polymorphisms at the interleukin 12B (IL-12B), IL-23A, IL-23 receptor (IL-23R), tumor necrosis factor-a induced protein 3 (TNFAIP3), and TNIP1 (TNFAIP3 interacting protein 1) loci [1 –5]. Investigating susceptibility loci in patients with psoriasis vulgaris (PsV) and psoriatic arthritis (PsA) may help to determine w...
Conclusions The pharmacological treatment of psoriasis was in accordance with the recommendations of the clinical practice guidelines, but the high proportion of potentially inappropriate prescriptions makes it necessary to promote educational and pharmacovigilance strategies that improve the formulation habits of the physicians involved in the treatment of these patients.
Purpose of review To give an overview of the recently published trials relating to IL-23/IL-17 pathway in spondyloarthritis (SpA). Recent findings Recent studies in psoriasis confirmed the efficacy of targeting the IL-23/IL-17 pathway, with emerging evidence from head-to-head studies suggesting functional hierarchy of these inhibitors. In psoriatic arthritis (PsA), recent studies have indicated the efficacy of inhibiting IL-23p19, in addition to IL-23p40 and IL-17A, albeit all with lower hurdle results than those seen in psoriasis. The first head-to-head study of an IL-17A and tumour necrosis factor inhibitor in PsA h...
CONCLUSIONS: The real impact of anti-TNF-α therapy on the development of AITD remains an open question. The available studies concern the adult population; there are no data regarding this problem in children. Due to the increasing use of anti-TNF-α therapy also in the paediatric population, it seems reasonable to evaluate this subject in this group of patients. PMID: 32462852 [PubMed - as supplied by publisher]
Psoriasis is a chronic inflammatory disease of the skin and joints that is strongly associated with the major histocompatibility complex (MHC) region ; it is estimated to affect more than 125 million people worldwide . The most common type of psoriasis is chronic plaque psoriasis (also known as psoriasis vulgaris: PV), which accounts for about 90 % of cases . Approximately 6 % –42 % of psoriasis patients are also affected by chronic arthritis (psoriatic arthritis: PsA) in their lifetime .
Guselkumab, a biologic drug approved to treat patients with moderate or severe psoriasis, significantly and safely improved psoriatic arthritis, a phase 3 trial in The Lancet concluded. Guselkumab is a human monoclonal antibody that inhibits interleukin-23.
Co-stimulatory T-cell inhibitors are used in the treatment of rheumatoid arthritis and to prevent rejection of renal transplants. Inhibitors of the intereukin (IL-17) cytokine are indicated for psoriasis, psoriatic arthritis and ankylosing spondylitis and anti- IL-23 drugs for psoriasis. Serious infections occur in 4.2% to 25.0% of co-stimulatory inhibitors and 1.0% to 2.0% with IL-17 or IL-23 inhibitors. Underlying disease, steroid dose greater than 7.5 to 10.0 mg, and comorbidities influence risk in individual patients. Opportunistic infections or reactivation of tuberculosis are rare.